High affinity copper binding by stefin B (cystatin B) and its role in the inhibition of amyloid fibrillation

FEBS Journal

Volumn 273, Issue 18, 2006, Pages 4250-4263

  Žerovnik, Eva ^a   Škerget, Katja ^a   Tušek Žnidarič, Magda ^b   Loeschner, Corina ^c   Brazier, Marcus W ^c   Brown, David R ^c  

^a JO EF STEFAN INSTITUTE   (Slovenia)

^b NATIONAL INSTITUTE OF BIOLOGY   (Slovenia)

^c University of Bath   (United Kingdom)

Author keywords

Copper binding proteins; Cystatin; Inhibition of amyloid fibril formation; Oligomers; Protein aggregation; Stefin B

Indexed keywords

AMYLOID; COPPER; CYSTATIN B; CYSTEINE PROTEINASE INHIBITOR; STEFIN B;

ARTICLE; BINDING AFFINITY; CONFORMATIONAL TRANSITION; ELECTRON MICROSCOPY; FLUORESCENCE ANALYSIS; HUMAN; ISOTHERMAL TITRATION CALORIMETRY; LIGAND BINDING; OLIGOMERIZATION; PH; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BINDING;

AMINO ACID SEQUENCE; AMYLOID; CIRCULAR DICHROISM; COPPER; CYSTATINS; FLUORESCENCE; HUMANS; HYDROGEN-ION CONCENTRATION; MICROSCOPY, ELECTRON, TRANSMISSION; MOLECULAR SEQUENCE DATA; MULTIPROTEIN COMPLEXES; MUTATION; PROTEIN CONFORMATION; PROTEIN ISOFORMS; SEQUENCE ALIGNMENT; THIAZOLES;

EID: 33748304111     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2006.05426.x     Document Type: Article

References (55)

1. Guijarro JI, Sunde M, Jones JA, Campbell ID & Dobson CM (1998) Amyloid fibril formation by an SH3 domain. Proc Natl Acad Sci USA 95, 4224-4228.
2. Dobson CM (1999) Protein misfolding, evolution and disease. Trends Biochem Sci 24, 329-332.
3. Bucciantini M, Giannoni E, Chiti F, Baroni F, Formigli L, Zurdo J, Taddei N, Ramponi G, Dobson CM & Stefani M (2002) Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416, 507-511.
4. Raman B, Ban T, Yamaguchi K, Sakai M, Kawai T, Naiki H & Goto Y (2005) Metal ion-dependent effects of clioquinol on the fibril growth of an amyloid {beta} peptide. J Biol Chem 280, 16157-16162.
5. Žerovnik E, Pompe-Novak M, Škarabot M, Ravnikar M, Muševič I & Turk V (2002) Human stefin B readily forms amyloid fibrils in vitro. Biochim Biophys Acta 1594, 1-5.
6. Jenko S, Škarabot M, Kenig M, Gunčar G, Muševič I, Turk D & Žerovnik E (2004) Different propensity to form amyloid fibrils by two homologous proteins-Human stefins A and B: searching for an explanation. Proteins 55, 417-425.
7. Matsunaga Y, Žerovnik E, Yamada T & Turk V (2002) Conformational changes preceding amyloid-fibril formation of amyloid-beta and stefin B; parallels in pH dependence. Curr Med Chem 9, 1717-1724.
8. Anderluh G, Gutierrez-Aguirre I, Rabzelj S, Čeru S, Kopitar-Jerala N, Maček P, Turk V & Žerovnik E (2005) Interaction of human stefin B in the prefibrillar oligomeric form with membranes. Correlation with cellular toxicity. FEBS J 272, 3042-3051.
9. Rawlings ND, Tolle DP & Barrett AJ (2004) MEROPS: the peptidase database. Nucleic Acids Res 32, D160-D164.
10. Turk V & Bode W (1991) The cystatins: protein inhibitors of cysteine proteinases. FEBS Lett 285, 213-219.
11. Turk V, Turk B & Turk D (2001) Lysosomal cysteine proteinases: facts and opportunities. EMBO J 20, 4629-4633.
12. Stubbs MT, Laber B, Bode W, Huber R, Jerala R, Lenarčič B & Turk V (1990) The refined 2.4 Å X-ray crystal structure of recombinant human stefin B in complex with the cysteine proteinase papain: a novel type of proteinase inhibitor interaction. EMBO J 9, 1939-1947.
13. Jenko S, Dolenc I, Gunčar G, Doberšek A, Podobnik M & Turk D (2003) Crystal structure of stefin A in complex with cathepsin H: N-terminal residues of inhibitors can adapt to the active sites of endo- and exopeptidases. J Mol Biol 326, 875-885.
14. Martin JR, Craven CJ, Jerala R, Kroon-Žitko L, Žerovnik E, Turk V & Waltho JP (1995) The three-dimensional solution structure of human stefin A. J Mol Biol 246, 331-343.
15. Jerala R & Žerovnik E (1999) Accessing the global minimum conformation of stefin A dimer by annealing under partially denaturing conditions. J Mol Biol 291, 1079-1089.
16. Staniforth RA, Giannini S, Higgins LD, Conroy MJ, Hounslow AM, Jerala R, Craven CJ & Waltho JP (2001) Three-dimensional domain swapping in the folded and molten-globule states of cystatins, an amyloid-forming structural superfamily. EMBO J 20, 4774-4781.
17. Janowski R, Kozak M, Jankowska E, Grzonka Z, Grubb A, Abrahamson A & Jaskolski M (2001) Human cystatin C, an amyloidogenic protein, dimerizes through three-dimensional domain swapping. Nat Struct Biol 8, 316-320.
18. Di Giamo R, Riccio M, Santi S, Galeotti C, Ambrosetti DC & Melli M (2002) New insights into the molecular basis of progressive myoclonus epilepsy: a multiprotein complex with cystatin B. Hum Mol Genet 11, 2941-2950.
19. Riccio M, Di Giaimo R, Pianetti S, Palmieri PP, Melli M & Santi S (2001) Nuclear localization of cystatin B, the cathepsin inhibitor implicated in myoclonus epilepsy (EPM1). Exp Cell Res 262, 84-94.
20. Pennacchio LA, Bouley DM, Higgins KM, Scott MP, Noebels JL & Myers RM (1998) Progressive ataxia, myoclonic epilepsy and cerebellar apoptosis in cystatin B-deficient mice. Nat Genet 20, 251-258.
21. Lieuallen K, Pennacchio LA, Park M, Myers RM & Lennon GG (2001) Cystatin B-deficient mice have increased expression of apoptosis and glial activation genes. Hum Mol Genet 10, 1867-1871.
22. Pennacchio LA, Lehesjoki AE, Stone NE, Willour VL, Virtaneva K, Miao J, D'Amato E, Raminez L, Faham M, Koskiniemi M et al. (1996) Mutations in the gene encoding cystatin B in progressive myoclonus epilepsy (EPM1). Science 271, 1731-1734.
23. Alakurtti K, Weber E, Rinne R, Theol G, Haan G, Lindhout D, Salmikangas P, Saukko P, Lahtinen U & Lehesjoki A (2004) Loss of lysosomal association of cystatin b proteins representing progressive myoclonus epilepsy, EPM1, mutations. Eur J Hum Genet 13, 208-215.
24. D'Amato E, Kokaia Z, Nanobashvili A, Reeben M, Lehesjoki AE, Saarma M & Lindvall O (2000) Seizures induce widespread upregulation of cystatin B, the gene mutated in progressive myoclonus epilepsy, in rat forebrain neurons. Eur J Neurosci 12, 1687-1695.
25. Pirttilä TJ, Lukasiuk K, Håkansson K, Grubb A, Abrahamson M & Pitkänen A (2005) Cystatin C modulates neurodegeneration and neurogenesis following status epilepticus in mouse. Neurobiol Dis 20, 241-253.
26. Deng A, Irizarry MC, Nitsch RM, Growdon JH & Rebeck GW (2001) Elevation of Cystatin C in Susceptible Neurons in Alzheimer's Disease. Am J Pathol 159, 1061-1068.
27. Ii K, Hidehumi I, Kominami E & Hirano A (1993) Abnormal distribution of cathepsin proteinases and endogenous inhibitors (cystatins) in the hippocampus of patients with Alzheimer's disease, parkinsonism-dementia complex on Guam, and senile dementia and in the aged. Virchows Arch a Pathol Anat Histopathol 423, 185-194.
28. Manning MC & Woody RW (1989) Theoretical study of the contribution of aromatic side chains to the circular dichroism of basic bovine pancreatic trypsin inhibitor. Biochemistry 28, 8609-8613.
29. Whitmore L & Wallace BA (2004) DICHROWEB, an online server for protein secondary structure analyses from circular dichroism spectroscopic data. Nucleic Acids Res 32, W668-W673.
30. Lobley A, Whitmore L & Wallace BA (2002) DICHROWEB: an interactive website for the analysis of protein secondary structure from circular dichroism spectra. Bioinformatics 18, 211-212.
31. Žerovnik E, Jerala R, Kroon-Žitko L, Pain RH & Turk V (1992) Intermediates in denaturation of a small globular protein, recombinant human stefin B. J Biol Chem 267, 9041-9046.
32. Jensson O, Palsdottir A, Thorsteinsson L, Arnason A, Abrahamson M, Olafsson I & Grubb A (1990) Cystatin C mutation causing amyloid angiopathy and brain hemorrhage. Biol Chem Hoppe Seyler 371 (Suppl.), 229-232.
33. Sastre M, Calero M, Pawlik M, Mathews PM, Kumar A, Danilov V, Schmidt SD, Nixon RA, Frangione B & Levy E (2004) Binding of cystatin C to Alzheimer's amyloid beta inhibits in vitro amyloid fibril formation. Neurobiol Aging 25, 1033-1043.
34. Sanders A, Craven JC, Higgins LD, Giannini S, Conroy MJ, Hounslow AM, Waltho JP & Staniforth RA (2004) Cystatin forms a tetramer through structural rearrangement of domain-swapped dimers prior to amyloidogenesis. J Mol Biol 336, 165-178.
35. Modler AJ, Gast K, Lutsch G & Damaschun G (2003) Assembly of amyloid protofibrils via critical oligomers - a novel pathway of amyloid formation. J Mol Biol 325, 135-148.
36. Knaus KJ, Morillas M, Swietnicki W, Malone M, Surewicz WK & Yee VC (2001) Crystal structure of the human prion protein reveals a mechanism for oligomerization. Nat Struct Biol 8, 770-774.
37. Walsh DM, Hartley DM, Kusumoto Y, Fezoui Y, Condron MM, Lomakin A, Benedek GB, Selkoe DJ & Teplow DB (1999) Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J Biol Chem 274, 25945-25952.
38. Lashuel HA, Hartley D, Petre BM, Walz T & Lansbury PT (2002) Amyloid pores pathogenic mutations. Nature 418, 291-291.
39. Rabzelj S, Turk V & Žerovnik E (2005) In vitro study of stability and amyloid-fibril formation of two mutants of human stefin B (cystatin B) occurring in patients with EPM1. Protein Sci 14, 2713-2722.
40. Brown DR, Qin K, Herms JW, Madlung A, Manson J, Strome R, Fraser PE, Kruck T, von Bohlen A, Schulz-Schaeffer W, Giese A, Westaway D & Kretzschmar H (1997) The cellular prion protein binds copper in vivo. Nature 390, 684-687.
41. Qin K, Yang DS, Yang Y, Chishti MA, Meng LJ, Kretzschmar HA, Yip CM, Fraser PE & Westaway D (2000) Copper (II)-induced conformational changes and protease resistance in recombinant and cellular PrP. Effect of protein age and deamidation. Biol Chem 275, 19121-19131.
42. Tsenkova RN, Iordanova IK, Toyoda K & Brown DR (2004) Prion protein fate governed by metal binding. Biochem Biophys Res Commun 325, 1005-1012.
43. Brown DR, Hafiz F, Glasssmith LL, Wong B-S, Jones IM, Clive C & Haswell SJ (2000) Consequences of manganese replacement of copper for prion protein function and proteinase resistance. EMBO J 19, 1180-1186.
44. Rasia RM, Bertoncini CW, Marsh D, Hoyer W, Cherny D, Zweckstetter M, Griesinger C, Jovin TM & Fernandez CO (2005) Structural characterization of copper (II) binding to alpha-synuclein: Insights into the bioinorganic chemistry of Parkinson's disease. Proc Natl Acad Sci USA 102, 4294-4299.
45. Hesse L, Beher D, Masters CL & Multhaup G (1994) The beta A4 amyloid precursor protein binding to copper. FEBS Lett 349, 109-116.
46. Atwood CS, Scarpa RC, Huang X, Moir RD, Jones WD, Fairlie DP, Tanzi RE & Bush AI (2000) Characterization of copper interactions with alzheimer amyloid beta peptides: identification of an attomolar-affinity copper binding site on amyloid beta1-42. J Neurochem 75, 1219-1233.
47. Borchardt T, Camakaris J, Cappai R, Masters CL, Beyreuther K & Multhaup G (1999) Copper inhibits beta-amyloid production and stimulates the non-amyloidogenic pathway of amyloid-precursor-protein secretion. Biochem J 344, 461-467.
48. 2+ (II) is induced by conditions representing physiological acidosis. J Biol Chem 273, 12817-12826.
49. Eakin CM, Berman AJ & Miranker AD (2005) A native to amyloidogenic transition regulated by a backbone trigger. Nat Struct Biol 13, 202-208.
50. Houseweart MK, Pennacchio LA, Vilaythong A, Peters C, Noebels JL & Myers RM (2003) Cathepsin B but not cathepsins L or S contributes to the pathogenesis of Unverricht-Lundborg progressive myoclonus epilepsy (EPM1). J Neurobiol 56, 315-327.
51. Ritonja A, Machleidt W & Barrett AJ (1985) Amino acid sequence of the intracellular cysteine proteinase inhibitor cystatin B from human liver. Biochem Biophys Res Commun 131, 1187-1192.
52. Jerala R, Trstenjak M, Lenarčič B & Turk V (1988) Cloning a synthetic gene for human stefin B and its expression in E. coli. FEBS Lett 239, 41-44.
53. Thompsett AR, Abdelraheim SR, Daniels M & Brown DR (2005) High affinity binding between copper and full-length prion protein identified by two different techniques. J Biol Chem 280, 42750-42758.
54. 2+ (II) binding to His, GlyGlyHis, HisGlyHis, and bovine serum albumin: a critical evaluation. Inorg Chem 39, 3057-3064.
55. Dawson RMC, Elliot DC, Elliot DH & Jones KM (1986) Data for Biochemical Research. 3rd edn. Oxford University Press, Oxford.